Purpose The role of estrogen receptor beta (ER-β) expression in pancreatic ductal adenocarcinoma (PDAC) is largely unknown. Ligand-independent phosphorylation and activation of ER-β may play a relevant role in the IL-6/STAT3 signaling pathway and, as a result, in tumor progression. Here, we examined the effect of ER-β, phosphorylated ER-β (pER-β), STAT3, phosphorylated STAT3 (pSTAT3) and IL-6 expression on the overall and recurrence-free survival in a cohort of patients with resected PDAC. Methods We identified 175 patients who underwent pancreatic resection for PDAC. Tissue microarrays were constructed from the archival tumor specimens. These were stained with specific antibodies for the above molecules. The expression of the markers was then correlated with clinicopathological parameters and survival analysis was performed. Results High nuclear expression of ER-β was found in 61.7% and pER-β in 80.6% of the tumors. STAT3 was expressed in 54.3% of the tumor samples, pSTAT3 in 68% and IL-6 in 76.6%. The median overall survival for patients with low pER-β expression was 29 months, whereas for patients with high pER-β expression was 15.1 months (p = 0.016). Multivariate analysis revealed that pER-β expression was an independent factor correlating with shorter overall survival (hazard ratio 1.9; p = 0.013) and disease-free survival (hazard ratio 1.9; p = 0.029). Conclusions Expression of pER-β constitutes an independent prognostic marker for PDAC and is correlated with poor prognosis. These data may help in identifying novel drug targets in PDAC and patients who could benefit from additional therapeutic regimens, including selective estrogen receptor modulators.
Introduction
The treatment of pancreatic ductal adenocarcinoma (PDAC) remains challenging despite the progress in surgical techniques and drug therapy. Due to its typical late presentation and its refractory nature, PDAC has the worst survival rate of all cancers, with a 5-year survival rate of < 5% (Nakao et al. 2006; Hirono et al. 2010 ) and the median survival remains between 10 and 20 months (Yeo et al. 1995 (Yeo et al. , 1997 Millikan et al. 1999) . Clinical trials have shown that chemotherapy has limited impact on the natural history of the disease (Denley et al. 2013) . Thus, the underlying molecular mechanisms involved in pancreatic carcinogenesis require further investigation to identify novel targets for therapeutic intervention.
The incidence of PDAC varies by sex and is greater in younger men than in younger women (Zhang et al. 2008 ), but this difference decreases with increasing age. This has raised interest in sex hormones and their receptors in the development of pancreatic cancer (Andrén-Sandberg et al. 1999; Imamura and Mizuno 2005) . In 1981, Greenway et al. first reported the presence of estrogen receptors (ERs) in pancreatic cancer tissue (Greenway et al. 1981 ). Since then, diverse studies with controversial results have investigated the presence and role of estrogen receptors (ERs) in pancreatic cancer, as well as the role of selective estrogen receptor modulators (SERMs) in its therapy (Singh et al. 1997; Yeh et al. 2002; Ollayos et al. 1994; Iwao et al. 2001; Satake et al. 2006) . Newer studies demonstrated that ERs interact with cell membranes and signal transduction proteins in the absence of ligand activating diverse intracellular pathways (Ellmann et al. 2009 ).
SERMs are competitive inhibitors of estrogen binding to ERs and have a mixed antagonistic/agonistic effect on ERs, depending on the target tissue. SERMs increase the bone density providing partial protection against menopausal bone loss. The molecular mechanism of their effect on bone tissue is not fully understood, but the cytokine interleukin-6 (IL-6) plays a key role. IL-6 mediates the increase in bone resorption that occurs following estrogen deficiency (Bryant et al. 1999; Jilka et al. 1992) . The aforementioned effect of SERMs on bone tissue is transmitted through the ERs, suggesting a possible interaction between ER and IL-6. In pancreatic cancer, key signaling pathways are dysregulated contributing to pancreatic tumorigenesis. One of the essential signaling cascades in pancreatic cancer initiation and progression constitutes the IL-6/STAT3 pathway (STAT3: signal transducer and activator of transcription-3) (Lesina et al. 2014) .
The objective of this study was to examine the effect of the expression of ER-β, phosphorylated ER-β (pER-β), IL-6, STAT3 and phosphorylated STAT3 (pSTAT3 Tyr705 ) on overall survival and recurrence-free survival in a cohort of patients with resected PDAC. These molecules and their signaling pathways may be a promising therapeutic target for the treatment of PDAC in the future.
Materials and methods

Patients
In total, 211 patients who underwent surgical therapy of PDAC at the Department of Surgery at the Hospital of the Ludwig-Maximilians-University of Munich between 2003 and 2010 were considered for this study. Exclusion criteria were perioperative mortality (patients dying within 30 days after curative resection), the presence of macroscopic residual disease after resection and periampullary tumors other than PDAC, e.g., ampullary, distal cholangiocarcinomas, and duodenal adenocarcinomas. Thirty-six patients were excluded and 175 patients were finally included in the analysis.
Data on clinicopathological parameters and follow-up information were extracted from the local tumor registry and clinical records. The study was approved by the Ethics Committee of the Hospital of the University of Munich.
Tissue microarrays
Archival tumor specimens (paraffin tissues) from the Institute of Pathology of the Ludwig-Maximilians-University of Munich were analyzed and tissue micro-arrays (TMAs) were constructed according to standard procedures as previously described (Knösel et al. 2005 (Knösel et al. , 2006 . Two TMAs containing 422 samples from 211 patients were constructed. The PDAC TMA was assembled using 0.6-mm punch biopsies from all 211 samples. In total, 2110 specimens of pancreatic tissue including normal mucosa were evaluated.
Immunohistochemistry
Commercial antibodies employed were: ER-β (Novocastra Laboratories Ltd, Newcastle upon Tyne, UK); pER-β Ser105 (Abcam, Cambridge, UK); STAT3 (Abcam, Cambridge, UK); pSTAT3 Tyr705 (Cell Signaling Technology, Danvers, MA, USA) and IL-6 (Abcam, Cambridge, UK). Immunohistological staining of TMAs was performed according to standard procedures. Briefly, the TMA slides were pretreated and then incubated with the antibodies, followed by antibody detection via biotinylated anti-mouse secondary antibody and a biotin-streptavidin amplified detection system (Biogenex, San Ramon, CA, USA). Staining was visualized using a Fastred chromogen system (DAKO, Hamburg, Germany). The TMA slides were evaluated by a pathologist blinded for the clinical data. The immunostaining of the cells concerning the expression of ER-β and pER-β was evaluated and scored according to the immunoreactive score of Remmele and Stegner (IRS) with a range between 0 and 12 (Remmele and Stegner 1987) . For statistical evaluation, scores 0 and 1 were considered as low expression, whereas scores of 2 or higher were considered as high expression. The immunohistochemical staining of the other three molecules (STAT3, pSTAT3 and IL-6) was scored semiquantitatively by a fourtier scale (0, negative; 1, weak; 2, moderate; 3, strongly positive) according to standard procedures (Knösel et al. 2006) . This was reduced also to a two-tier system (0, negative; 1-3, positive) for the independently performed statistical analysis of single protein and its correlation with clinicopathological parameters including survival.
Statistical analysis
Data were analyzed with SPSS software, version 20.0 (IBM Corp., Armonk, NY, USA). Overall survival was defined as the time interval between the date of resection and the date of death from any cause, or censoring based on the date of last contact. p values of < 0.05 were considered statistically significant. The association between expression of the investigated parameters and clinicopathological characteristics was tested with Chi square test. Kaplan-Meier curves and univariate survival analysis were performed for each investigated parameter. Survival curves were compared and assessed using the log-rank test. Multivariate survival analysis was performed using a proportional hazard model (Cox regression). Apart from age and sex, only parameters with p values < 0.05 in univariate survival analysis were included. As UICC Stadium summarizes the parameters of tumor size, lymph node status and the presence or absence of metastasis (TNM), these factors were not included separately in the Cox proportional risk model (Greene 2003) . A stepwise procedure, including both backward elimination and forward selection, was used to analyze the independent prognostic factors.
Results
Clinicopathological parameters
The study population consisted of 94 males and 81 females ranging from 32 to 88 years (median 68.4 years). The majority of patients were older than 60 years (76%) and underwent partial pancreatoduodenectomy (PD: Whipple procedure, 34.9%) or pylorus-preserving partial pancreatoduodenectomy (PPPD: pp-Whipple, 44.6%) for tumors in the head of the pancreas. As shown in Table 1 , most of tumor samples showed advanced tumor infiltration (pT3 = 84.6%) and lymph node involvement (pN1 = 64%), whereas 8.6% of the patients had already developed distant metastases. The median number of lymph nodes analyzed was 13 (range 0-41). The histopathological examination showed high-grade tumors (G2 and G3) in the great majority (96.5%) of tissue samples and microscopic residual disease after resection in 42.3% of the tumors. Most patients underwent perioperative chemotherapy (33.2%) or a chemoradiotherapy (45.1%), whereas 21.7% of the patients had no additional therapy. The characteristics of the study subjects are summarized in Table 1 .
Immunohistochemical analysis
High nuclear expression of ER-β was found in 61.7% and pER-β in 80.6% of the tumors. A significant proportion of the tumor samples expressed STAT3 (54.3%) and pSTAT3 (68%). Expression of IL-6 was observed in 76.6% of the specimens ( Table 2) . Expression of the molecules was also observed in the cytoplasmic cellular compartments. Representative examples of immunohistochemical staining of PDAC tissue microarrays for ER-β and IL-6/STAT3 pathway proteins are shown in Fig. 1 . No significant correlation of clinicopathological parameters with the expression of the molecules was found (data not shown).
Survival analysis
The median overall survival was 16.3 months and the mean overall survival 32.9 months [confidence interval (CI) 95% 27.2-38.6]. The median disease-free survival was 33.9 months and the mean disease-free survival 15.5 months (CI 95% 27.0-40.7). At the end of follow-up, 32 patients (18.3%) were alive.
Correlation of clinicopathological parameters with patient survival
Overall survival was significantly related to tumor stage (stage I-IIa vs. stage IIb-IV, p = 0.031), metastasis (M0 vs. M1, p < 0.001), grading (low vs. high, p = 0.002) and residual tumor (status R0 vs. R1, p = 0.022). Age, sex, tumor size, lymph node status and perioperative radiochemotherapy were not related to the overall survival rates (Table 3) . (Table 4) .
Correlation of expression of ER-β and STAT3/IL-6 pathway proteins in PDAC tissue with patient survival
The median overall survival for patients with low pER-β expression was 29 months, whereas for patients with high pER-β expression was 15.1 months (p = 0.016). The median disease-free survival for patients with low and high pER-β expression was 16.7 and 14.8 months, respectively (p = 0.042). The median overall survival of patients with low pER-β expression was at least 14 months longer in comparison with patients with high pER-β expression. All other investigated molecules showed no significant prognostic relevance (p > 0.05). The corresponding survival curves according to the antibodies investigated (ER-β, pER-β, STAT3, pSTAT3 and IL-6 expression) are shown in Figs. 2 and 3.
Multivariate survival analysis
For multivariate analysis, the following variables were taken into account: age, sex, tumor stage, grading, residual tumor, pER-β expression (Tables 3, 4 ). High expression of pER-β, high tumor grading (G2 and G3) and presence of microscopic residual tumor proved to be independent predictors of overall survival in patients with PDAC correlating with a bad prognosis. Patients with high pER-β expression had a shorter overall survival with a hazard ratio of 1.9 (95% CI 1.1-3.3; p = 0.013). Multivariate analysis revealed high expression of pER-β, UICC stadium, high tumor grading and presence of microscopic residual tumor as independent predictors of a shorter disease-free survival (Table 4) . Patients with high pER-β expression were almost twice as likely to have a recurrence compared with patients with low pER-β expression (hazard ratio 1.9; 95% CI 1.1-3.4; p = 0.029).
Discussion
Estrogen receptor-related pathways are involved in the pathogenesis of pancreatic cancer, representing a suitable target for its treatment (Nacusi and Debes 2008) . Although several studies about anti-hormone treatment with SERMs (e.g., tamoxifen) in PDAC showed controversial results (Satake et al. 2006; Taylor et al. 1993; Konduri and Schwarz 2007) , ligand-independent activation of ERs (e.g., phosphorylation) and therapeutic perspectives of this pathway remain unexplored in pancreatic cancer (Nacusi and Debes 2008) .
Several studies have been published investigating the presence of ERs in pancreatic tumors, but the results are inconsistent. Some studies reported the presence of ERs, although others failed to detect ERs at all (Singh et al. 1997; Yeh et al. 2002; Ollayos et al. 1994; Iwao et al. 2001) . As well, the expression of the two ER isoforms, ER-α and ER-β, in pancreatic tumors remains controversial. Satake et al. reported that more than 90% of all published studies used antibodies that specifically recognized only the ER-α isoform. The expression pattern of ER-β in pancreatic cancer remains unclear to date (Satake et al. 2006) . Moreover, there are data showing that ER-β may play a more important role than ER-α in pancreatic cancer (Iwao et al. 2001) . A recent study investigating in vitro pancreatic cell proliferation showed that ERs are frequently expressed in pancreatic cancer cell lines and especially ER-β expression usually outweighs ER-α expression (Konduri and Schwarz 2007) . Our study is in line with these data showing that the majority of pancreatic tumors strongly express ER-β and pER-β. Furthermore, our data showed that pER-β was notably identified as an independent predictor of disease outcome for PDAC correlating with poor prognosis. This result provides additional strong evidence for ER-β in particular having an important role in PDAC. The fact that some tumors express strongly only the phosphorylated form of ER-β could be explained on the grounds that the phosphorylation of the ER-β reduces the percentage of non-phosphorylated ER-β in the pancreatic cancer cell. ER-β was also present in the majority of the rest of the tumors, but not strongly expressed, so that they were rated as "1" and categorized as "low expression".
Several studies investigating the role of ER-β in breast cancer have reported that ER-β might serve as a favorable prognostic factor, although the data are not entirely consistent (Maehle et al. 2009 ). The expression of ER-β is a protective factor in colorectal cancer (Fang et al. 2010) . In prostate cancer the loss of ER-β expression is associated with progression from normal prostate epithelium to cancer, while those cancers that retain ER-β expression are associated with a higher recurrence rate (Horvath et al. 2001). ER-β is a prognostic marker of a favorable course of non-small cell lung cancer (Atmaca et al. 2014) . Apart from the tumors mentioned above, there are also some studies regarding esophageal, ovarian and brain tumors (Dong et al. 2013 , Simpkins et al. 2013 , Sareddy et al. 2012 ). While they provide inconsistent results demonstrating the complex role of ER-β in cancer, ER-β expression seems to have predominantly a tumor-suppressive role in the tumors mentioned above. Nevertheless, our findings suggest that ER-β may have a tumor-promoting effect on pancreatic cancer, illustrating that several molecular mechanisms might be underlying the differential influence of ER-β in tumors, as for example, ligand affinity, gene transcription, interactions with co-factors, heterogeneous dimerizations or splice variants of receptors.
The present human PDAC cohort demonstrated that, while the expression of the phosphorylated active form of ER-β correlates significantly with poor overall and diseasefree survival, ER-β showed no association with survival. This suggests that the phosphorylation of ER-β at serine 105 in the pancreatic cell may be an important component of pancreatic tumorigenesis resulting in poor prognosis. ER activity is regulated at multiple levels including phosphorylation, one of the most important posttranslational modifications. It occurs in response to hormone and ligand-independent signals modulating ER transcriptional competence and mediating genomic and non-genomic action of the receptor. Specific phosphorylation sites were identified in the activation function-1 (AF-1), which is located in the N terminus of the ER-α. Phosphorylation of the ER-α at serine sites has been reported to alter protein-protein interaction, subcellular localization, transactivation and the stability of the human ER-α (Lannigan 2003; Le et al. 2011) . Multiple phosphorylation sites on the human ER-α were shown to influence breast cancer carcinogenesis. In contrast, our knowledge of human ER-β phosphorylation was derived primarily through studies of the mouse ER-β (Tremblay et al. 1999) . However, further information on the influence of ER-β phosphorylation on carcinogenesis is still not available and requires further investigation.
Immunohistochemical staining in our cohort of patients demonstrated that ER-β and mainly the phosphorylated active form pER-β are found not only in the nuclear but also in the cytoplasmic cellular compartments. This observation suggests that ER-β is not only active in the nucleus but it also has non-genomic or indirect genomic activity in the cytoplasm, where it could interact with other signaling molecules. Similar to other NRs, the two ER isoforms are generally classified as ligand-dependent transcription factors. After the association with their specific ligands, they bind specific genomic sequences (EREs) and interact with co-regulators to regulate gene expression. In addition to the classical ligand-induced activation of ERs, recent studies described that ERs can be also transcriptionally activated in the absence of ligand by undergoing selected posttranslational modifications that modify their stability, cellular localization and activity (e.g., phosphorylation) (Heldring et al. 2007; Ellmann et al. 2009 ). The unliganded activated ERs then interact with other signaling molecules in the nucleus or in the cytoplasm regulating the activity of other major signaling cascades (Heldring et al. 2007; Nacusi and Debes 2008; Lange et al. 2007; Lee et al. 2001; Cheskis et al. 2007; Ellmann et al. 2009 ). A previous study described the role of nuclear receptor phosphorylation showing the ligand-independent activation of ERβ via the MAPK pathway (Tremblay et al. 1999) . In the absence of ligands, the cascade of signaling events is different and either activation or repression may occur. A ligand-independent signaling pathway is thought to activate the ERs in cancerous tissues contributing to hormone-independent tumor growth (Heldring et al. 2007; Shim et al. 2000; Coutts and Murphy 1998) .
Previous studies showed that raloxifene suppresses IL-6 and inhibits mammalian osteoclast differentiation and bone resorption activity only in the presence of IL-6, suggesting a possible interaction between ER and IL-6 (Bryant et al. 1999; Jilka et al. 1992) . Importantly, Yamamoto et al. reported that active ER directly associates with, and acts as a transcriptional co-factor for, STAT3 induced by IL-6 in breast cancer cells. Moreover, direct physical interactions between STAT3 and ER were also reported, which represent a novel form of cross-talk between STAT3 and ER signaling pathways and open up novel therapeutic prospects (Yamamoto et al. 2000) . Based on the data above, this study focused on the ER-β and its phosphorylated form pER-β. Furthermore, we also investigated three other molecules (STAT3, pSTAT3 and IL-6), which are part of an important signaling cascade in tumor progression.
The IL-6/STAT3 pathway constitutes one of the essential signaling cascades in pancreatic cancer initiation and progression (Lesina et al. 2014) . Recent studies demonstrated that stimulation with IL-6 activates phosphorylation of STAT3 in pancreatic cell lines (Block et al. 2012; Huang et al. 2010; Adam et al. 2009 ) and that the JAK/ STAT pathway also stimulates cell proliferation and malignant transformation and inhibits apoptosis in the pancreas (Yu and Kim 2012) . IL-6 plays a major role in malignant transformation and progression of several tumors, including pancreatic cancer (Syed et al. 2002; Block et al. 2012; Lesina et al. 2014; Barillé et al. 2000 ; Lou et al. . IL-6 acts either by affecting the tumor cells directly or modulating the tumor microenvironment. A study in KRAS-mutated mice showed the major role of IL-6 in PDAC reporting that IL-6 activates STAT3 pathway in order for the early PanIN lesions to be developed to PDAC (Lesina et al. 2011) . Moreover, elevated IL-6 levels are described in pancreatic cancer and correlated with poor prognosis (Lesina et al. 2011; Bellone et al. 2005 ) as well as with weight loss and cachexia, which are negative prognostic factors for patients with pancreatic cancer (Falconer et al. 1994; Okada et al. 1998 ). Furthermore, IL-6 promotes angiogenesis in tumors (Roshani et al. 2014) .
Immunohistochemical staining in our cohort of patients confirms the data above, as the majority of the examined pancreatic tumors express all three of the investigated components of IL-6/STAT3 pathway, supporting the importance of this cascade in pancreatic cancer. However, our survival analysis demonstrated no prognostic relevance of IL-6/STAT3 pathway proteins. Denley et al. reported that expression of IL-6R, JAK, STAT3 and pSTAT3Ser727 is not associated with the survival in a tissue microarray-based cohort of PDAC from 86 patients undergoing pancreaticoduodenectomy, confirming our results about STAT3 and IL-6 expression. In contrast, high pSTAT3
Tyr705 expression was associated with reduced overall survival in univariate and multivariate analysis. Furthermore, Denley et al. reported high phosphorylated JAK (pJAK) expression as an independent adverse prognostic factor, and patients with a combination of high expression of pJAK and pSTAT3
Tyr705 had an especially poor prognosis (Denley et al. 2013) . As far as prognostic relevance of pSTAT3
Tyr705 is concerned, there has been only limited assessment of its prognostic utility in pancreatic cancer. Comprising 175 patients, our cohort represents to date the largest study investigating the expression of the IL-6/JAK/STAT3 signaling pathway in PDAC. However, despite diverse studies trying to determine the clinicopathological impact of this inflammatory pathway in resectable PDAC, IL-6/STAT3 pathway proteins in pancreatic tumorigenesis and tumor progression is not fully understood.
While the majority of patients in this study were treated with adjuvant therapy, it should also be mentioned that the lack of a standardized adjuvant therapy protocol is a drawback. While many patients were treated only with chemotherapy, other patients were treated with a combination of adjuvant radiochemotherapy. Further evaluation of the molecules expressed and their prognostic relevance is required in a cohort with a standardized adjuvant therapy protocol, as adjuvant therapy could affect survival rates. Nevertheless, in the present study, the expression of the investigated molecules was not statistically associated with the type of adjuvant therapy.
Conclusion
All five investigated molecules (ER-β, pER-β, STAT3, pSTAT3 and IL-6) were expressed in more than half of the examined pancreatic tumors. Especially, pER-β was strongly expressed in the majority of tumors and its expression constitutes an independent poor prognostic marker for PDAC. However, the understanding of the molecular mechanisms and the exact role of ER-β/pER-β and IL-6/STAT3 pathways in the cellular cascades in PDAC could potentially identify prognostic subtypes of PDAC and define novel therapeutic targets. Furthermore, the lack of detailed studies evaluating the therapy with SERMs only to patients expressing ERs probably contributes to the inconsistency of published results concerning therapy with SERMs in pancreatic cancer. The present study suggests a thorough re-examination of the potential role of SERMs in pancreatic neoplasms with high pER-β expression. These data may help in identifying patients who could benefit from additional therapeutic regimens, including selective estrogen receptor modulators.
